Subscribe To
Agios presents updated pyrukynd® (mitapivat) data highlighting long-term safety profile and durable improvement in hemoglobin and markers of hemolysis and ineffective erythropoiesis in non-transfusion
– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T Studies Evaluating PYRUKYND® in Adults with Non-transfusion-dependent and Transfusion-dependen...
December 10, 2022, 11:30 pm
Agios presents updated pyrukynd® (mitapivat) data highlighting long-term safety profile and durable improvement in hemoglobin and markers of hemolysis and ineffective erythropoiesis in non-transfusion
– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T Studies Evaluating PYRUKYND® in Adults with Non-transfusion-dependent and Transfusion-dependen...
December 10, 2022, 11:30 pm
Agios presents updated pyrukynd® (mitapivat) data highlighting long-term safety profile and durable improvement in hemoglobin and markers of hemolysis and ineffective erythropoiesis in non-transfusion
– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T Studies Evaluating PYRUKYND® in Adults with Non-transfusion-dependent and Transfusion-dependen...
December 10, 2022, 11:30 pm
Agios presents updated pyrukynd® (mitapivat) data highlighting long-term safety profile and durable improvement in hemoglobin and markers of hemolysis and ineffective erythropoiesis in non-transfusion
– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T Studies Evaluating PYRUKYND® in Adults with Non-transfusion-dependent and Transfusion-dependen...
December 10, 2022, 11:30 pm
Agios presents updated pyrukynd® (mitapivat) data highlighting long-term safety profile and durable improvement in hemoglobin and markers of hemolysis and ineffective erythropoiesis in non-transfusion
– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T Studies Evaluating PYRUKYND® in Adults with Non-transfusion-dependent and Transfusion-dependen...
December 10, 2022, 11:30 pm
Agios presents updated pyrukynd® (mitapivat) data highlighting long-term safety profile and durable improvement in hemoglobin and markers of hemolysis and ineffective erythropoiesis in non-transfusion
– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T Studies Evaluating PYRUKYND® in Adults with Non-transfusion-dependent and Transfusion-dependen...
December 10, 2022, 11:30 pm
Agios presents updated pyrukynd® (mitapivat) data highlighting long-term safety profile and durable improvement in hemoglobin and markers of hemolysis and ineffective erythropoiesis in non-transfusion
– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T Studies Evaluating PYRUKYND® in Adults with Non-transfusion-dependent and Transfusion-dependen...
December 10, 2022, 11:30 pm
Agios presents updated pyrukynd® (mitapivat) data highlighting long-term safety profile and durable improvement in hemoglobin and markers of hemolysis and ineffective erythropoiesis in non-transfusion
– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T Studies Evaluating PYRUKYND® in Adults with Non-transfusion-dependent and Transfusion-dependen...
December 10, 2022, 11:30 pm
Agios presents updated pyrukynd® (mitapivat) data highlighting long-term safety profile and durable improvement in hemoglobin and markers of hemolysis and ineffective erythropoiesis in non-transfusion
– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T Studies Evaluating PYRUKYND® in Adults with Non-transfusion-dependent and Transfusion-dependen...
December 10, 2022, 11:30 pm
Agios presents updated pyrukynd® (mitapivat) data highlighting long-term safety profile and durable improvement in hemoglobin and markers of hemolysis and ineffective erythropoiesis in non-transfusion
– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T Studies Evaluating PYRUKYND® in Adults with Non-transfusion-dependent and Transfusion-dependen...
December 10, 2022, 11:30 pm
Sutro biopharma announces presentation of stro-002 data from the compassionate use program in pediatric patients with relapsed/refractory cbf/glis aml at ash 2022
– A total of 17 pediatric patients were treated with STRO-002 on a compassionate use basis; eight patients achieved complete remission, of which sev...
December 10, 2022, 3:30 pm
Fate therapeutics announces clinical safety and activity data of first-ever ipsc-derived car t-cell therapy at 2022 ash annual meeting
FT819 Off-the-Shelf CAR T-cell Product Candidate Derived from Clonal Engineered Master iPSC Line with Novel CD19-specific 1XX CAR Integrated into TRAC...
December 10, 2022, 3:00 pm
Beam therapeutics: expected to boost pipeline development into 2023
Beam Therapeutics announced the recruitment of its first BEACON trial patient in the middle of November 2022. BEAM's announcement was followed by Edit...
December 9, 2022, 5:05 pm
How amazon, lowe's and mastercard can potentially 6x your retirement income
High-yield aristocrats are a great way to generate generous, safe, and growing yield today. But if you want to truly retire in ...
December 9, 2022, 11:30 am
Adyen: superior business model with margin of safety
Adyen's significant multiple contraction and the 50% decline in its share price deliver a robust margin of saf...
December 9, 2022, 10:12 am
Pfizer and biontech get fda fast track designation for single-dose covid and flu vaccine candidate
Pfizer Inc. PFE, +3.07% and German partner BioNTech SE BNTX, +5.64% said Friday they have received fast track designation from the U.S. Food and Drug ...
December 9, 2022, 6:54 am
Five ways that markets are signaling a slowing economy
Recent economic data showed surprising strength in the US service sector via the ISM services report and non-farm payrolls but markets are looking ...
December 8, 2022, 8:51 pm
Blackberry's (bb) qnx platform leveraged by human horizons
Human Horizons will be using BlackBerry's (BB) QNX Neutrino Realtime Operating System (RTOS), QNX OS for safet...
December 8, 2022, 12:48 pm
Dentsply sirona: don't sink your teeth into this health care stock
The Health Care sector has been a recent source of safety as volatility perks back up. One mid-sized do...
December 8, 2022, 12:33 pm
Aim immunotech reports positive safety, tolerability, and biological activity data from phase 1 ampligen study
AIM ImmunoTech Inc (NYSE:AIM) has reported positive safety, tolerability, and biological activity data from a Phase 1 study involving the intranasal a...
December 8, 2022, 9:06 am